DE69911602D1 - Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten - Google Patents

Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten

Info

Publication number
DE69911602D1
DE69911602D1 DE69911602T DE69911602T DE69911602D1 DE 69911602 D1 DE69911602 D1 DE 69911602D1 DE 69911602 T DE69911602 T DE 69911602T DE 69911602 T DE69911602 T DE 69911602T DE 69911602 D1 DE69911602 D1 DE 69911602D1
Authority
DE
Germany
Prior art keywords
formulations containing
aerosol formulations
pharmaceutical aerosol
beta agonist
pressure dosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69911602T
Other languages
English (en)
Other versions
DE69911602T2 (de
Inventor
E Blondino
Michael Brucato
W Buenafe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ivax Research Holdings Inc
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Publication of DE69911602D1 publication Critical patent/DE69911602D1/de
Application granted granted Critical
Publication of DE69911602T2 publication Critical patent/DE69911602T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69911602T 1998-06-19 1999-06-18 Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten Expired - Fee Related DE69911602T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/099,779 US6451285B2 (en) 1998-06-19 1998-06-19 Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US99779 1998-06-19
PCT/US1999/013863 WO1999065460A2 (en) 1998-06-19 1999-06-18 Pressurized metered dose inhalers and pharmaceutical aerosol formulations comprising a beta-agonist

Publications (2)

Publication Number Publication Date
DE69911602D1 true DE69911602D1 (de) 2003-10-30
DE69911602T2 DE69911602T2 (de) 2004-07-01

Family

ID=22276581

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69911602T Expired - Fee Related DE69911602T2 (de) 1998-06-19 1999-06-18 Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten
DE69915144T Expired - Fee Related DE69915144T2 (de) 1998-06-19 1999-06-18 Aerosoldruckdosiergeräte und Aerosolarzneizusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69915144T Expired - Fee Related DE69915144T2 (de) 1998-06-19 1999-06-18 Aerosoldruckdosiergeräte und Aerosolarzneizusammensetzungen

Country Status (23)

Country Link
US (2) US6451285B2 (de)
EP (2) EP1306082B1 (de)
JP (1) JP2002518100A (de)
KR (1) KR20010053025A (de)
CN (2) CN1154477C (de)
AR (1) AR018891A1 (de)
AT (2) ATE250409T1 (de)
AU (1) AU762927B2 (de)
BR (1) BR9912170A (de)
CA (1) CA2335303A1 (de)
CO (1) CO5031245A1 (de)
DE (2) DE69911602T2 (de)
DK (2) DK1085856T3 (de)
ES (2) ES2205848T3 (de)
HU (1) HUP0102468A3 (de)
IL (1) IL140340A0 (de)
NO (1) NO20006466L (de)
PL (1) PL345399A1 (de)
PT (2) PT1306082E (de)
RU (1) RU2214230C2 (de)
SK (1) SK19442000A3 (de)
WO (1) WO1999065460A2 (de)
ZA (1) ZA200007455B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
CZ303833B6 (cs) 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosolový prostredek
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
RU2294737C2 (ru) * 2001-03-30 2007-03-10 Яготек Аг Медицинские аэрозольные составы
DE60103527T2 (de) * 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
MXPA04008372A (es) * 2002-03-01 2004-11-26 Chiesi Farma Spa Formulacion superfina de formoterol.
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
KR101369631B1 (ko) * 2002-08-21 2014-03-05 노턴 헬스케어 리미티드 흡입용 조성물
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2010253776B2 (en) * 2009-05-29 2015-01-22 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
EP3020393B1 (de) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulierungen und verfahren zur steuerung der mdi-partikelgrössenfreisetzung
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
BR112018011266B1 (pt) 2015-12-04 2023-11-21 Mexichem Fluor S.A. De C.V. Composição farmacêutica, recipiente vedado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica
JP6781830B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
JP6781828B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
ES2957459T3 (es) 2016-09-19 2024-01-19 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (de) 1957-01-31 1957-04-11
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
AU8055691A (en) 1990-06-29 1992-01-23 Fisons Plc Pressurised aerosol compositions
DE69105212T2 (de) 1990-10-18 1995-03-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzubereitung, die beclometason 17,21-dipropionat enthält.
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de) 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
DE69218455T2 (de) 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzungen für arzneimittelsuspensionen
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
DE59206234D1 (de) 1991-12-31 1996-06-13 Hoechst Ag Medizinische Aerosolformulierung
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
IES80485B2 (en) 1996-12-04 1998-08-12 Bioglan Ireland R & D Ltd Pharmaceutical compositions and devices for their administration
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol

Also Published As

Publication number Publication date
AU4825999A (en) 2000-01-05
HUP0102468A3 (en) 2002-12-28
NO20006466L (no) 2001-02-16
NO20006466D0 (no) 2000-12-18
DK1085856T3 (da) 2003-12-08
ATE260093T1 (de) 2004-03-15
KR20010053025A (ko) 2001-06-25
ZA200007455B (en) 2002-06-13
EP1306082B1 (de) 2004-02-25
WO1999065460A2 (en) 1999-12-23
JP2002518100A (ja) 2002-06-25
PL345399A1 (en) 2001-12-17
AR018891A1 (es) 2001-12-12
PT1085856E (pt) 2004-01-30
PT1306082E (pt) 2004-05-31
ATE250409T1 (de) 2003-10-15
DE69915144D1 (de) 2004-04-01
DE69915144T2 (de) 2004-12-09
RU2214230C2 (ru) 2003-10-20
SK19442000A3 (sk) 2001-09-11
US6451285B2 (en) 2002-09-17
EP1085856B1 (de) 2003-09-24
AU762927B2 (en) 2003-07-10
CN1310611A (zh) 2001-08-29
CA2335303A1 (en) 1999-12-23
US20020018753A1 (en) 2002-02-14
BR9912170A (pt) 2001-10-23
DK1306082T3 (da) 2004-06-01
CN1522692A (zh) 2004-08-25
ES2215153T3 (es) 2004-10-01
CO5031245A1 (es) 2001-04-27
HUP0102468A2 (hu) 2002-03-28
EP1085856A2 (de) 2001-03-28
US20030077230A1 (en) 2003-04-24
ES2205848T3 (es) 2004-05-01
DE69911602T2 (de) 2004-07-01
WO1999065460A3 (en) 2000-04-27
IL140340A0 (en) 2002-02-10
CN1154477C (zh) 2004-06-23
EP1306082A1 (de) 2003-05-02

Similar Documents

Publication Publication Date Title
DE69911602D1 (de) Druckdosierinhalator und pharmazeutische aerosol formulierungen enthaltend einen beta-agonisten
HUS1800032I1 (hu) Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
ATE228823T1 (de) Pharmazeutische aerosolformulierung
EE04259B1 (et) Survestatud doseerivad inhalaatorid (MDId)
DE69912781T2 (de) Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
EE04451B1 (et) Pulberinhalaatori kapsel farmatseutiliste preparaatide mahutamiseks
PL348809A1 (en) Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol
NO307864B1 (no) Farmasøytisk aerosolformulering, boks og doseringsinhalator
DK0883415T3 (da) Inhalator til pulverformigt medikament
DK0837710T3 (da) Lægemiddelpulverpatron med integreret doseringsindretning og inhalator for lægemidler på pulverform
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
NO20026055D0 (no) Farmasöytisk komponent omfattende human paratyroidhormon og farmasöytisk komponent for nasal administrering inneholdende komponentene
ATE447964T1 (de) Eine pharmazeutische formulierung, enthaltend einen inhibitor der carboxypeptidase a und einen thrombin-inhibitor
GB0024326D0 (en) Composition containing a herbal medicinal substance and a pharmaceutical drug

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee